

AWTTC Letter template for information

Ref:

Date:

Address:

Dear (insert)

Name of medicine (X) / indication

The All Wales Medicines Strategy Group (AWMSG) advises Welsh Government on the availability of new medicines within NHS Wales. In November 2013, and with regard to equity in Welsh patients' access to medicines, AWMSG agreed to consider applications for appraisal of medicines which have previously received a negative recommendation from the National Institute for Health and Care Excellence (NICE) on the grounds of lack of cost-effectiveness, but which are funded in England via alternative national commissioning routes.

The All Wales Therapeutics & Toxicology Centre (AWTTC) provides administrative, scientific and clinical support to AWMSG. As the AWMSG Secretariat, we understand that the above medicine may fall within this category and we wish to encourage your company to take this opportunity to engage with the appraisal process in Wales.

An opportunity exists for you to make an application for the above medicine to be appraised by AWMSG. Please note that your application will be expected to include a Wales Patient Access Scheme, but it is likely to also include;

- additional information which may not have been available to NICE, or which may have become available subsequent to the NICE appraisal
- information specific to NHS Wales (perhaps highlighting a specific patient population or other societal benefit/s) or
- a differing approach to the economic analysis which recognises that AWMSG considers a broad strategic, societal and patient perspective to its recommendations

In order that AWTTC can better consider your evidence of value or benefit to NHS Wales over and above that considered by NICE, we would be happy to have dialogue (either by teleconference or videoconference) where you can informally discuss whether this type of information would enable consideration by AWMSG.

For example:

- Outcome data not available at the time of NICE appraisal (e.g. new clinical trial evidence)
- Data that have become available subsequent to the NICE appraisal (e.g. case study reports from usage due to alternative funding in England or elsewhere)
- Interpretation of plausible clinical scenarios which may be particularly relevant to NHS Wales (e.g. greater incidence or relevance of disease in Wales)
- Societal issues relevant to Wales (e.g. issues relating to equity of access in England or elsewhere)
- Where application of AWMSG's orphan/ultra-orphan/EoL policy could make a difference to the appraisal outcome (e.g. noting that previous positive AWMSG appraisal recommendations have on occasions been overturned by subsequent negative NICE guidance)

AWMSG is keen to ensure that patients living in Wales have timely access to new clinically-effective and cost-effective medicines. Please email awttc@wales.nhs.uk indicating whether or not you will be submitting a request to engage in the AWMSG process.

We look forward to hearing from you.

Yours sincerely

Ruth Lang (Mrs)
Head of Liaison & Administration